New Diabetes Biomarker Kit Bridges the Glycation Gap
By LabMedica International staff writers Posted on 02 Mar 2015 |
A newly released diabetes biomarker assay was designed to close the information gap between daily blood glucose testing and the two-three month HbA1c (glycated hemoglobin) reading.
The new Glycated Serum Protein (GSP) LiquiColor assay, which has both [US] Food and Drugs Administration and European CE approval, is manufactured by the EKF Diagnostics (Cardiff, United Kingdom) subsidiary Stanbio Chemistry.
The GSP LiquiColor test is based on a double enzymatic degradation method that utilizes the specificity of fructosyl-amino oxidase to eliminate inaccuracies caused by non-glycated protein reducing substances, which significantly interfere with the NBT fructosamine method. The test is available as a liquid-stable kit with calibrator. It is suitable for use on a variety of clinical chemistry analyzers, with on-board stability of up to four weeks.
“GSP can provide a helpful supplement to glucose and HbA1c testing, when assessing glycemic control for the management of diabetic patients, especially in cases where HbA1c may be inaccurate,” said Al Blanco, business unit director at EKF Diagnostics. “GSP bridges the glycation gap, which is the difference between actual measured HbA1c and predicted HbA1c from glycated serum protein, to provide improved prediction of diabetic complications.”
Related Links:
EKF Diagnostics
The new Glycated Serum Protein (GSP) LiquiColor assay, which has both [US] Food and Drugs Administration and European CE approval, is manufactured by the EKF Diagnostics (Cardiff, United Kingdom) subsidiary Stanbio Chemistry.
The GSP LiquiColor test is based on a double enzymatic degradation method that utilizes the specificity of fructosyl-amino oxidase to eliminate inaccuracies caused by non-glycated protein reducing substances, which significantly interfere with the NBT fructosamine method. The test is available as a liquid-stable kit with calibrator. It is suitable for use on a variety of clinical chemistry analyzers, with on-board stability of up to four weeks.
“GSP can provide a helpful supplement to glucose and HbA1c testing, when assessing glycemic control for the management of diabetic patients, especially in cases where HbA1c may be inaccurate,” said Al Blanco, business unit director at EKF Diagnostics. “GSP bridges the glycation gap, which is the difference between actual measured HbA1c and predicted HbA1c from glycated serum protein, to provide improved prediction of diabetic complications.”
Related Links:
EKF Diagnostics
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines